The Effect of NN1250 in Subjects With Type 2 Diabetes of Different Race and/or Ethnic Origin
Status:
Completed
Trial end date:
2010-10-01
Target enrollment:
Participant gender:
Summary
This trial is conducted in the United States of America (USA). The aim of this trial is to
investigate the pharmacodynamic (effect) and pharmacokinetic (exposure of drug) properties of
NN1250 (insulin degludec, IDeg) in subjects with type 2 diabetes of different race and/or
ethnicity.